AEON Biopharma, Inc. — Operating Income by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8f8d2af3-d2d6-49a5-8750-4a72ddfe0e04/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-12.8M | 2025-01-01 – 2025-12-31 | evidence 0001837607-26-000019 |
| FY 2024 | $73.0M | 2024-01-01 – 2024-12-31 | evidence 0001837607-25-000022 |
| FY 2022 | $-48.4M | 2022-01-01 – 2022-12-31 | evidence 0001837607-24-000015 |
| FY 2021 | $-1.9M | 2021-01-01 – 2021-12-31 | evidence 0001104659-22-038759 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).